INOV Stock Overview
Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare.
Inovalon Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$41.06|
|52 Week High||US$41.06|
|52 Week Low||US$17.56|
|1 Month Change||0.69%|
|3 Month Change||1.16%|
|1 Year Change||122.07%|
|3 Year Change||229.80%|
|5 Year Change||167.49%|
|Change since IPO||52.07%|
Recent News & Updates
|INOV||US Healthcare Services||US Market|
Return vs Industry: INOV exceeded the US Healthcare Services industry which returned -4.5% over the past year.
Return vs Market: INOV exceeded the US Market which returned 24.3% over the past year.
|INOV Average Weekly Movement||0.6%|
|Healthcare Services Industry Average Movement||8.4%|
|Market Average Movement||6.3%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: INOV is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 1% a week.
Volatility Over Time: INOV's weekly volatility (1%) has been stable over the past year.
About the Company
Inovalon Holdings, Inc. provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, an integrated, real-time cloud native platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities.
Inovalon Holdings Fundamentals Summary
|INOV fundamental statistics|
Is INOV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INOV income statement (TTM)|
|Cost of Revenue||US$201.47m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.32|
|Net Profit Margin||6.73%|
How did INOV perform over the long term?See historical performance and comparison
Is Inovalon Holdings undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: INOV ($41.06) is trading above our estimate of fair value ($31.7)
Significantly Below Fair Value: INOV is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: INOV is poor value based on its PE Ratio (126.4x) compared to the US Healthcare Services industry average (105.8x).
PE vs Market: INOV is poor value based on its PE Ratio (126.4x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: INOV is poor value based on its PEG Ratio (3.7x)
Price to Book Ratio
PB vs Industry: INOV is overvalued based on its PB Ratio (8.3x) compared to the US Healthcare Services industry average (4.7x).
How is Inovalon Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INOV's forecast earnings growth (34.1% per year) is above the savings rate (2%).
Earnings vs Market: INOV's earnings (34.1% per year) are forecast to grow faster than the US market (14.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: INOV's revenue (11.7% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: INOV's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INOV's Return on Equity is forecast to be high in 3 years time
How has Inovalon Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INOV has high quality earnings.
Growing Profit Margin: INOV's current net profit margins (6.7%) are higher than last year (0.9%).
Past Earnings Growth Analysis
Earnings Trend: INOV's earnings have grown by 3.3% per year over the past 5 years.
Accelerating Growth: INOV's earnings growth over the past year (784.3%) exceeds its 5-year average (3.3% per year).
Earnings vs Industry: INOV earnings growth over the past year (784.3%) exceeded the Healthcare Services industry 4.8%.
Return on Equity
High ROE: INOV's Return on Equity (6.8%) is considered low.
How is Inovalon Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: INOV's short term assets ($366.3M) exceed its short term liabilities ($152.6M).
Long Term Liabilities: INOV's short term assets ($366.3M) do not cover its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: INOV's net debt to equity ratio (107.5%) is considered high.
Reducing Debt: INOV's debt to equity ratio has increased from 37.1% to 121.7% over the past 5 years.
Debt Coverage: INOV's debt is not well covered by operating cash flow (12.5%).
Interest Coverage: INOV's interest payments on its debt are not well covered by EBIT (2x coverage).
What is Inovalon Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INOV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INOV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INOV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INOV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INOV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Keith Dunleavy (52 yo)
Dr. Keith R. Dunleavy, M.D., has been the Chairman of Inovalon Holdings, Inc. since 2006 and its Chief Executive Officer since 1998 and is its Founder. Dr. Dunleavy is responsible for the overall execution...
CEO Compensation Analysis
Compensation vs Market: Keith's total compensation ($USD211.83K) is below average for companies of similar size in the US market ($USD6.20M).
Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.
Experienced Management: INOV's management team is considered experienced (2.2 years average tenure).
Experienced Board: INOV's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Inovalon Holdings, Inc.'s employee growth, exchange listings and data sources
- Name: Inovalon Holdings, Inc.
- Ticker: INOV
- Exchange: NasdaqGS
- Founded: 1998
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$6.374b
- Shares outstanding: 155.25m
- Website: https://www.inovalon.com
Number of Employees
- Inovalon Holdings, Inc.
- 4321 Collington Road
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/24 23:16|
|End of Day Share Price||2021/11/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.